Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic DifferentiationMaría E. Figueroa, Ari Melnick, Bob Löwenberg et al.|Cancer Cell|2010Cited by 2.7k
Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (<i>R</i>)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (PF-06821497)Pei‐Pei Kung, Martin P. Edwards, Patrick Bingham et al.|Journal of Medicinal Chemistry|2017Cited by 128
Identification of genes associated with cancer progression and prognosis in lung adenocarcinoma: Analyses based on microarray from Oncomine and The Cancer Genome Atlas databasesWei Liu, Liping Dai, Songyun Ouyang et al.|Molecular Genetics & Genomic Medicine|2018Cited by 58
Cryptotanshinone inhibits breast cancer cell growth by suppressing estrogen receptor signalingShanhu Li, Jianguang Zhou, Hongtao Wang et al.|Cancer Biology & Therapy|2014Cited by 46
The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiationBenjamin Mizukawa, Yi Zheng, Eric O’Brien et al.|Blood|2017Cited by 46